An Open-label, Multicenter, Phase I Safety Study of AXT-1003 in Subjects With Advanced Malignant Tumors
Latest Information Update: 27 Mar 2025
At a glance
- Drugs AXT 1003 (Primary)
- Indications Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Axter Therapeutics
Most Recent Events
- 27 Sep 2024 Status changed from not yet recruiting to recruiting.
- 15 Jul 2024 New trial record